Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study.
Papaioannou AI, Kallieri M, Zervas E, Fouka E, Porpodis K, Hadji Mitrova M, Tzortzaki E, Makris M, Ntakoula M, Lyberopoulos P, Dimakou K, Koukidou S, Ampelioti S, Papaporfyriou A, Katsoulis K, Kipourou M, Rovina N, Antoniou K, Vittorakis S, Bakakos P, Steiropoulos P, Markopoulou K, Avarlis P, Papanikolaou ΙC, Markatos M, Gaki E, Samitas K, Glynos K, Papiris SA, Papakosta D, Tzanakis N, Gaga M, Kostikas K, Loukides S. Papaioannou AI, et al. Among authors: samitas k. Allergy Asthma Proc. 2025 Jan 1;46(1):45-51. doi: 10.2500/aap.2025.46.240084. Allergy Asthma Proc. 2025. PMID: 39741370
The Role of Biomarkers in Lung Cancer Screening.
Boutsikou E, Hardavella G, Fili E, Bakiri A, Gaitanakis S, Kote A, Samitas K, Gkiozos I. Boutsikou E, et al. Among authors: samitas k. Cancers (Basel). 2024 May 23;16(11):1980. doi: 10.3390/cancers16111980. Cancers (Basel). 2024. PMID: 38893101 Free PMC article. Review.
Levels of IgE sensitization drive symptom thresholds in allergic rhinitis.
Dimou MV, Xepapadaki P, Lakoumentas J, Mageiros L, Aggelidis X, Antonopoulou M, Bakakos P, Βotskariova S, Chliveros K, Chrysoulakis S, Dimas D, Douladiris N, Gaga M, Grigoreas C, Kalogiros L, Katotomichelakis M, Kompoti E, Constantinidis J, Koutsogianni Z, Loukides S, Makris M, Manousakis E, Marangoudakis P, Marmara M, Mikos N, Mitsakou P, Mitsias D, Pagalos A, Papanikolaou V, Paraskevopoulos I, Pitsios C, Psarros F, Rovina N, Samitas K, Stefanaki E, Vallianatou M, Vourdas D, Tsiligianni I, Bousquet J, Papadopoulos NG. Dimou MV, et al. Among authors: samitas k. Ann Allergy Asthma Immunol. 2024 Aug;133(2):177-185.e10. doi: 10.1016/j.anai.2024.04.026. Epub 2024 Apr 26. Ann Allergy Asthma Immunol. 2024. PMID: 38679157
Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.
Kallieri M, Papaioannou AI, Zervas E, Fouka E, Porpodis K, Hadji Mitrova M, Tzortzaki E, Makris M, Ntakoula M, Lyberopoulos P, Dimakou K, Koukidou S, Ampelioti S, Papaporfyriou A, Katsoulis K, Kipourou M, Rovina N, Antoniou K, Vittorakis S, Bakakos P, Steiropoulos P, Markopoulou K, Avarlis P, Papanikolaou ΙC, Markatos M, Gaki E, Samitas K, Glynos K, Papiris SA, Papakosta D, Tzanakis N, Gaga M, Kostikas K, Loukides S. Kallieri M, et al. Among authors: samitas k. Clin Exp Allergy. 2024 Apr;54(4):286-290. doi: 10.1111/cea.14436. Epub 2023 Dec 12. Clin Exp Allergy. 2024. PMID: 38084474 No abstract available.
Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis.
Kroes JA, Alfonso-Cristancho R, Bansal AT, Berret E, Bieksiene K, Bourdin A, Brussino L, Canhoto D, Cardini C, Celik G, Csoma Z, Dahlén B, Damadoglu E, Eger K, Gauquelin L, Gemicioglu B, Goksel O, Graff S, Heffler E, Hofstee HB, Howarth P, Jakes RW, Jaun F, Kalinauskaite-Zukauske V, Kopač P, Kwon N, Loureiro CC, Lozoya García V, Masoli M, Rezelj MP, Pérez De Llano L, Popović-Grle S, Ramos-Barbón D, Sà Sousa A, Samitas K, Schleich F, Sirena C, Skrgat S, Zervas E, Zichnalis G, Bel EH, Sont JK, Hashimoto S, Ten Brinke A. Kroes JA, et al. Among authors: samitas k. ERJ Open Res. 2023 Apr 3;9(2):00745-2022. doi: 10.1183/23120541.00745-2022. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 37020841 Free PMC article.
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.
Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, Shalata W, Riudavets M, Christopoulos P, Girard N, Albarrán-Artahona V, Garcia Campelo R, Samitas K, Banna GL, Boukovinas I, Agbarya A, Koumarianou A, Perdikouri EI, Kosmidis P, Linardou H, Mauri D, Mavroudis D, Athanasiadis I, Kalofonos H, Xenidis N, Korantzis I, Ardavanis A, Rallis G, Bottiglieri A, Efthymiadis K, Oikonomopoulos G, Kokkalis A, Saloustros E, Tsoukalas N, Bartzi D, Economopoulou P, Psyrri A, Reck M, Lo Russo G. Mountzios G, et al. Among authors: samitas k. JTO Clin Res Rep. 2022 Nov 20;4(1):100433. doi: 10.1016/j.jtocrr.2022.100433. eCollection 2023 Jan. JTO Clin Res Rep. 2022. PMID: 36793384 Free PMC article.
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.
Dimitrakopoulos FI, Mountzios G, Christopoulos P, Papastergiou T, Elshiaty M, Daniello L, Zervas E, Agelaki S, Samantas E, Nikolaidi A, Athanasiadis I, Baka S, Syrigos K, Christopoulou A, Lianos E, Samitas K, Tsoukalas N, Perdikouri EI, Oikonomopoulos G, Kottorou A, Kalofonou F, Makatsoris T, Koutras A, Megalooikonomou V, Kalofonos H. Dimitrakopoulos FI, et al. Among authors: samitas k. Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122728. doi: 10.1177/17588359221122728. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36105886 Free PMC article.
61 results